Sara M. Federico

发表

Abstract 6149: An innovative integrated cloud-based data portal for orthotopic patient-derived xenografts (O-PDX) available through the Childhood Solid Tumor Network (CSTN)

Xin Zhou, Anang A. Shelat, Xiang Chen, 2020 .

Targeting oxidative stress in embryonal rhabdomyosarcoma.

Heather L. Mulder, Erin K. Hedlund, Sara M. Federico, 2013, Cancer cell.

Comparison of PET–CT and conventional imaging in staging pediatric rhabdomyosarcoma

Sara M. Federico, S. Spunt, B. Shulkin, 2013, Pediatric blood & cancer.

Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma

Sara M. Federico, T. Merchant, A. Davidoff, 2022, Clinical and translational radiation oncology.

Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A

Michael W. Bishop, Sara M. Federico, Elizabeth Stewart, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma

Sara M. Federico, Elizabeth Stewart, A. Bahrami, 2019, Clinical Cancer Research.

Impact of MYCN Status on Response of High-Risk Neuroblastoma to Neoadjuvant Chemotherapy.

Sara M. Federico, A. Davidoff, W. Furman, 2019, Journal of pediatric surgery.

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma

Sara M. Federico, A. Pappo, R. Brennan, 2017, Clinical Cancer Research.

Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors

Anang A. Shelat, Elaine R. Mardis, Elizabeth Stewart, 2017, Nature.

Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.

Sara M. Federico, W. Furman, Jianrong Wu, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment

Sara M. Federico, C. Hillenbrand, J. Rehg, 2011, PloS one.

A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.

Sara M. Federico, A. Shelat, Elizabeth Stewart, 2020, European journal of cancer.

Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.

Sara M. Federico, A. Pappo, A. Davidoff, 2020, European journal of cancer.

Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma

Sara M. Federico, D. Cervi, W. Furman, 2019, Pediatric blood & cancer.

Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study.

Sara M. Federico, A. Bahrami, A. Pappo, 2016 .

Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults

Sara M. Federico, Kenneth J. Caldwell, Jessica Bodea, 2022, Frontiers in Oncology.

Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma

Sara M. Federico, A. Davidoff, W. Furman, 2021, Annals of Surgical Oncology.

Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma

Sara M. Federico, M. Dyer, Jiakun Zhang, 2011, Cancer.

Childhood cancer and developmental biology a crucial partnership.

Sara M. Federico, M. Dyer, R. Brennan, 2011, Current topics in developmental biology.

A bridge over troubled water—Extending induction for high‐risk neuroblastoma patients with poor end‐of‐induction response

Sara M. Federico, T. Cash, 2022, Cancer.

Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies

Sara M. Federico, S. Shurtleff, C. Pui, 2019, Clinical Cancer Research.

Development and characterization of a human orthotopic neuroblastoma xenograft

Sara M. Federico, Chunxu Qu, A. Shelat, 2015, Developmental biology.

Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.

Sara M. Federico, D. Frappaz, B. Geoerger, 2016, European journal of cancer.

Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor

Sara M. Federico, K. Somers, Sahr Yazdani, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies

Sara M. Federico, M. Wlodarski, R. Ribeiro, 2021, Blood advances.

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

Sara M. Federico, A. Pappo, M. Dyer, 2020, Journal for ImmunoTherapy of Cancer.

Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.

Sara M. Federico, P. Monagle, J. Rubnitz, 2018, The Lancet. Infectious diseases.

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

Jinghui Zhang, Matthew Parker, Elaine R Mardis, 2012, JAMA.

ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.

Sara M. Federico, M. Fowkes, J. Maris, 2019, Cancer cell.

MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Heather L. Mulder, Michael P. Meers, Shondra M. Pruett-Miller, 2018, Nature Communications.

The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities.

Sara M. Federico, A. Shelat, Elizabeth Stewart, 2016, Developmental biology.

Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series.

Sara M. Federico, W. Furman, B. Shulkin, 2020, Journal of pediatric hematology/oncology.

The role of chest computed tomography (CT) as a surveillance tool in children with high‐risk neuroblastoma

Sara M. Federico, S. Brady, A. Pappo, 2015, Pediatric blood & cancer.

Subsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma

Sara M. Federico, M. Hudson, S. Spunt, 2015, Journal of pediatric hematology/oncology.

Antigen cross-presentation in young tumor-bearing hosts promotes CD8+ T cell terminal differentiation

Shannon K. Boi, Sara M. Federico, J. Crawford, 2022, Science Immunology.

Visual Diagnosis: New Lung Nodules in a 3-year-old Girl with Wilms Tumor

Sara M. Federico, M. Weaver, 2016, Pediatrics in review.

Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

Wayne H. Liang, Sara M. Federico, A. Naranjo, 2020, JCO clinical cancer informatics.

The war on cancer: have we won the battle but lost the war?

Sara M. Federico, M. Dyer, R. Brennan, 2010, Oncotarget.

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

Sara M. Federico, B. Geoerger, F. Haluska, 2016, Oncotarget.

Orbital Metastasis Is Associated With Decreased Survival in Stage M Neuroblastoma

Sara M. Federico, Yimei Li, Xingyu Li, 2016, Pediatric blood & cancer.

Radiomics Features Differentiate Between Normal and Tumoral High-Fdg Uptake

Sara M. Federico, T. Merchant, S. Kaste, 2018, Scientific Reports.

Clinical impact of post‐induction resolution of pulmonary lesions in metastatic Ewing sarcoma

Sara M. Federico, S. Spunt, S. Kaste, 2020, Pediatric blood & cancer.

Clinical features and outcomes of young patients with head and neck non‐rhabdomyosarcoma soft tissue sarcomas

Sara M. Federico, S. Spunt, S. Samant, 2015, Head & neck.

Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).

Sara M. Federico, A. Pappo, A. Davidoff, 2017 .

FDG–PET CT in the evaluation of primary and secondary pancreatic malignancies

Sara M. Federico, A. Bahrami, G. Robinson, 2018, Pediatric blood & cancer.

SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents

Nathaniel R. Twarog, Sara M. Federico, Koon-Kiu Yan, 2021, Molecular Cancer Therapeutics.

Interrogation of SLFN11 in pediatric sarcomas uncovers an unexpected biological role and a novel therapeutic approach to overcoming resistance to replicative stress

Nathaniel R. Twarog, Sara M. Federico, Koon-Kiu Yan, 2020, bioRxiv.

Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

Fangyi Zhu, Kip Guy, Sara M. Federico, 2011, Cancer research.

Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients

Sara M. Federico, A. Place, A. Salem, 2023, Journal of Cancer.

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Sara M. Federico, M. Kool, G. Vassal, 2023, European journal of cancer.

Pain Outcomes After Celiac Plexus Block in Children and Young Adults with Cancer.

Sara M. Federico, D. Anghelescu, H. Prajapati, 2018, Journal of adolescent and young adult oncology.

Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.

Jamie L. Coleman, Sara M. Federico, A. Pappo, 2017 .

Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma: A Case Report

Sara M. Federico, Kohei Hagiwara, Jinghui Zhang, 2023, Research square.

Targeting the p 53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3 a

Sara M. Federico, M. Dyer, Jiakun Zhang, 2011 .

A piece of my mind. Ditch the Scale.

Sara M. Federico, 2015, JAMA.

Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors

Sara M. Federico, A. Davidoff, F. Navid, 2021 .

The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities.

Sara M. Federico, A. Shelat, Elizabeth Stewart, 2016, Developmental Biology.

Sara M. Federico, M. Kool, G. Vassal, 2023, European journal of cancer.